Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
hUC-MSCs for Stage II-III Knee Osteoarthritis
NCT06082440Phase 1Recruiting
- Sponsor
- Yejishan Hospital of Wannan Medical College
- Start
- Nov 2023
- Primary completion
- Aug 2025
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of human umbilical cord mesenchymal stem cells in knee osteoarthritis (OA), sponsored by Yejishan Hospital of Wannan Medical College. Primary endpoints: Incidence and severity of adverse events at 4 weeks and Maximum Tolerable Dose at 4 weeks. Started Nov 2023; status: recruiting.
02
Drugs
human umbilical cord mesenchymal stem cells
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on NCT06082440.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06082440.